O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, a marker that predicts response to temozolomide chemotherapy in glioblastoma, is one example that is already implemented in a clinical setting [44,45]. This evidence concerns the gene MGMT and glioblastoma.